Merck has announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, USA, access to Merck's foundational CRISPR intellectual property.

Promega will use Merck's CRISPR genome-editing technology to create research products and services, including those for drug development.

Merck's foundational CRISPR intellectual property will be used to develop CRISPR-edited cell lines, which can help determine drug efficacy and toxicity

"Under this licensing agreement, Promega plans to use our intellectual property to develop CRISPR-edited cell lines, which can play a major role in determining drug efficacy, toxicity and overall development," said Udit Batra, member of the Merck Executive Board and CEO, Life Science.

The agreement will allow researchers to better read the physiological or natural levels of protein expression, which provides a more accurate understanding of protein behavior.

"This license further expands the potential of CRISPR, and, more importantly, gives scientists a new view into natural cell activity,” saidBill Linton, president and CEO, Promega. "This is quite a meaningful contribution to many areas of applied research in such fields as cancer and neuroscience."

Promega is building a portfolio of CRISPR knock-in cell lines in addition to custom requests to meet the demands of customers studying protein dynamics.

Merck intends to continue growing its CRISPR intellectual property portfolio with technologies such as paired Cas9 nickases, which reduce off-target effects, and proxy-CRISPR, which offers researchers more experimental options to accelerate drug development and access to new therapies.

Merck holds 22 CRISPR-related patents worldwide covering both methods and compositions, including the fundamental use of CRISPR-Cas9 for genetic integration in mammalian cells.

Promega will use Merck's CRISPR genome-editing technology to create research products and services, including those for drug development.